Talphera Inc. (TLPH)

[murocman]

There will definitely be a market. It just remains to be seen how broadly this technology is used for pain control. Quite honestly, I think part of the battle will be the simple fact that hospital patients typically get an IV shunt as standard procedure. If it's already there, it might be hard to convince the cost reimbursement side to use a different delivery for pain control.

Given the prevalence of infections contracted in hospitals and the significant increase in risk the an IV creates in this realm, it will be interesting to see if there isn't a re-look at their use.

The is a very good presentation on the ACRX website under the Investors section (1/12/13 is the date I think). It does identify the market potential and several advantages of the system, but has no cost comparison data, which makes me think this solution is more expensive. The question is how much and is the ACRX solution going to be deemed compelling in spite of that?

Those are longer term questions that will get addressed by the FDA and the marketplace. Maybe we can get some practicing health professionals that can comment on some of these factors as well.

Murocman